Novartis (NVS) Projected to Post Quarterly Earnings on Wednesday

Novartis (NYSE:NVS) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Novartis to post earnings of $1.97 per share and revenue of $13.8502 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:00 AM ET.

Novartis Stock Up 1.6%

Shares of NYSE:NVS opened at $151.09 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.68 and a debt-to-equity ratio of 0.50. The firm has a market cap of $319.17 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.94 and a beta of 0.50. The stock’s 50-day moving average price is $138.88 and its two-hundred day moving average price is $129.95. Novartis has a 12-month low of $97.71 and a 12-month high of $152.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC purchased a new stake in shares of Novartis during the 3rd quarter valued at about $33,000. Pin Oak Investment Advisors Inc. grew its position in Novartis by 25.2% in the third quarter. Pin Oak Investment Advisors Inc. now owns 462 shares of the company’s stock valued at $59,000 after acquiring an additional 93 shares in the last quarter. Kelleher Financial Advisors purchased a new stake in shares of Novartis during the third quarter valued at approximately $75,000. Triumph Capital Management acquired a new position in shares of Novartis during the third quarter worth $79,000. Finally, Larson Financial Group LLC lifted its position in shares of Novartis by 34.3% during the third quarter. Larson Financial Group LLC now owns 1,420 shares of the company’s stock worth $182,000 after purchasing an additional 363 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of recent analyst reports. Bank of America upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a report on Tuesday, November 25th. Citigroup started coverage on shares of Novartis in a research note on Tuesday, January 27th. They set a “buy” rating for the company. TD Cowen restated a “hold” rating on shares of Novartis in a report on Monday, November 10th. JPMorgan Chase & Co. raised Novartis from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, Cfra set a $126.00 price target on Novartis and gave the company a “hold” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $119.75.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.